Maria A. S. Broggi

Maria A. S. Broggi

Auto-generated profile, based on publicly available information

Maria A. S. Broggi

Department of Biomedicine, Immunoregulation, University of Basel and University Hospital Basel

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2017 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
MFManuel Fankhauser
Manuel Fankhauser
MBMaria A. S. Broggi
Maria A. S. Broggi
LPLambert Potin
Lambert Potin
NBNatacha Bordry
Natacha Bordry
LJLaura Jeanbart
Laura Jeanbart
MSMelody A. Swartz
Melody A. Swartz
Tumor lymphangiogenesis, a driver of immunosuppression and metastasis, also potentiates immunotherapy.

15 August 2016 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ALAmanda W. Lund
Amanda W. Lund
MWMarek Wagner
Marek Wagner
MFManuel Fankhauser
Manuel Fankhauser
ESEli S. Steinskog
Eli S. Steinskog
MBMaria A. Broggi
Maria A. Broggi
MSMelody A. Swartz
Melody A. Swartz
Lymphatic remodeling in tumor microenvironments correlates with progression and metastasis, and local lymphatic vessels play complex and poorly understood roles in tumor immunity. Tumor lymphangiogenesis is associated with increased immune suppression, yet lymphatic vessels are required for fluid drainage and immune cell trafficking to lymph nodes, where adaptive immune responses are mounted. Here, we examined the contribution of lymphatic drainage to tumor inflammation and immunity using a mouse model that lacks dermal lymphatic vessels (K14-VEGFR3-Ig mice). Melanomas implanted in these mice grew robustly, but exhibited drastically reduced cytokine expression and leukocyte infiltration compared with those implanted in control animals. In the absence of local immune suppression, transferred cytotoxic T cells more effectively controlled tumors in K14-VEGFR3-Ig mice than in control mice. Furthermore, gene expression analysis of human melanoma samples revealed that patient immune parameters are markedly stratified by levels of lymphatic markers. This work suggests that the establishment of tumor-associated inflammation and immunity critically depends on lymphatic vessel remodeling and drainage. Moreover, these results have implications for immunotherapies, the efficacies of which are regulated by the tumor immune microenvironment.

14 January 2019 in Nature Materials
Verified
Journal Article
Closed access
PDF file
DWD. Scott Wilson
D. Scott Wilson
SHSachiko Hirosue
Sachiko Hirosue
MRMichal M. Raczy
Michal M. Raczy
LBLeonardo Bonilla-Ramirez
Leonardo Bonilla-Ramirez
LJLaura Jeanbart
Laura Jeanbart
JHJeffrey A. Hubbell
Jeffrey A. Hubbell

11 April 2019 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
MBMaria A.S. Broggi
Maria A.S. Broggi
LMLea Maillat
Lea Maillat
Cristina Corina ClementCristina Corina Clement
Cristina Corina Clement
NBNatacha Bordry
Natacha Bordry
PCPatricia Corthésy
Patricia Corthésy
MSMelody A. Swartz
Melody A. Swartz
Liquid biopsies allow monitoring of cancer progression and detection of relapse, but reliable biomarkers in melanoma are lacking. Because secreted factors preferentially drain to lymphatic vessels before dilution in the blood, we hypothesized that lymph should be vastly enriched in cancer biomarkers. We characterized postoperative lymphatic exudate and plasma of metastatic melanoma patients after lymphadenectomy and found a dramatic enrichment in lymphatic exudate of tumor-derived factors and especially extracellular vesicles containing melanoma-associated proteins and miRNAs, with unique protein signatures reflecting early versus advanced metastatic spread. Furthermore, lymphatic exudate was enriched in memory T cells, including tumor-reactive CD137+ and stem cell–like types. In mice, lymph vessels were the major route of extracellular vesicle transport from tumors to the systemic circulation. We suggest that lymphatic exudate provides a rich source of tumor-derived factors for enabling the discovery of novel biomarkers that may reflect disease stage and therapeutic response. Graphical Abstract

31 May 2018 in OncoImmunology
Verified
Journal Article
Open access
NBNatacha Bordry
Natacha Bordry
MBMaria A. S. Broggi
Maria A. S. Broggi
KJKaat de Jonge
Kaat de Jonge
KSKarin Schaeuble
Karin Schaeuble
PGPhilippe O. Gannon
Philippe O. Gannon
DSDaniel Speiser
Daniel Speiser
Increased density of tumor-associated lymphatic vessels correlates with poor patient survival in melanoma and other cancers, yet lymphatic drainage is essential for initiating an immune response. Here we asked whether and how lymphatic vessel density (LVD) correlates with immune cell infiltration in primary tumors and lymph nodes (LNs) from patients with cutaneous melanoma. Using immunohistochemistry and quantitative image analysis, we found significant positive correlations between LVD and CD8+ T cell infiltration as well as expression of the immunosuppressive molecules inducible nitric oxide synthase (iNOS) and 2,3-dioxygénase (IDO). Interestingly, similar associations were seen in tumor-free LNs adjacent to metastatic ones, indicating loco-regional effects of tumors. Our data suggest that lymphatic vessels play multiple roles at tumor sites and LNs, promoting both T cell infiltration and adaptive immunosuppressive mechanisms. Lymph vessel associated T cell infiltration may increase immunotherapy success rates provided that the treatment overcomes adaptive immune resistance.

8 October 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MSMathias Schmaler
Mathias Schmaler
MBMaria A. S. Broggi
Maria A. S. Broggi
NLNadège Lagarde
Nadège Lagarde
BSBenjamin F. Stöcklin
Benjamin F. Stöcklin
CKCarolyn G. King
Carolyn G. King
SRSimona W. Rossi
Simona W. Rossi
Significance: In mammals, regulatory T cells establish and maintain immune responses toward self- and non–self-antigens by suppression of specific T cells. Several mechanisms of suppression were previously described including starvation for IL-2, a cytokine required for T-cell expansion. Here we show that regulatory T cells (Treg) respond to IL-7, a T-cell survival factor produced by lymph node fibroblast reticular cells, by enhancing their IL-2 sensitivity, thereby limiting expansion of reactive T cells during inflammation. These findings highlight a previously unidentified and unexpected mechanism by which IL-7R signaling in Tregcells maintains peripheral and allograft tolerance. This work may contribute to design new therapeutic approaches using lower IL-2 doses in humans by enhancing the functional competence of regulatory T cells with IL-7.